PharmaCyte Biotech, Inc. (PMCB) stock
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$0.40+0.00 (+0.75%)
Close on Nov 12, 2026Market cap $4.32MP/E –Yield –
PharmaCyte Biotech cash
Cash and short-term investments held at the end of each period.
PharmaCyte Biotech's cash was $17.84M at Jul 31, 2026. For fiscal 2026 it was $18.86M, up 21.4% from the year before. Over ten years it grew 25.7% a year on average. The highest annual figure on record is $85.40M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $18.86M | +21.4% |
| FY2025 | Apr 30, 2025 | $15.54M | -69.0% |
| FY2024 | Apr 30, 2024 | $50.18M | -26.2% |
| FY2023 | Apr 30, 2023 | $68.04M | -20.3% |
| FY2022 | Apr 30, 2022 | $85.40M | +3778.1% |
| FY2021 | Apr 30, 2021 | $2.20M | +146.1% |
| FY2020 | Apr 30, 2020 | $894.86K | +73.7% |
| FY2019 | Apr 30, 2019 | $515.25K | -51.4% |
| FY2018 | Apr 30, 2018 | $1.06M | -69.4% |
| FY2017 | Apr 30, 2017 | $3.46M | +80.4% |
| FY2016 | Apr 30, 2016 | $1.92M | -28.9% |
| FY2015 | Apr 30, 2015 | $2.70M | -25.3% |
| FY2014 | Apr 30, 2014 | $3.62M | +1714.6% |
| FY2013 | Apr 30, 2013 | $199.30K | +1167.6% |
| FY2012 | Apr 30, 2012 | $15.72K | -72.5% |
| FY2011 | Apr 30, 2011 | $57.20K | +7889.0% |
| FY2010 | Apr 30, 2010 | $716 | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $17.84M | +14.8% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $18.86M | +12.5% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $20.54M | -1.5% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $15.61M | -52.2% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $15.54M | -69.0% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $16.76M | -72.6% |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $20.84M | -71.6% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $32.64M | -56.3% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $50.18M | -26.2% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $61.21M | -15.7% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $73.43M | -4.6% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $74.66M | -9.2% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $68.04M | -20.3% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $72.64M | -16.2% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $76.96M | -11.5% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $82.23M | +8471.9% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $85.40M | +3778.1% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $86.64M | +2703.0% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $86.94M | +2238.7% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $959.27K | -55.7% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $2.20M | +146.1% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $3.09M | +2073.0% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $3.72M | +8149.7% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $2.17M | +561.0% |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $894.86K | +73.7% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $142.24K | -79.7% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $45.06K | -95.0% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | $327.75K | -82.1% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $515.25K | -51.4% |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $699.46K | -53.6% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $907.42K | -66.2% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $1.83M | -57.2% |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | $1.06M | -69.4% |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $1.51M | -38.8% |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $2.68M | +72.9% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | $4.28M | +82.8% |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $3.46M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $2.46M | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $1.55M | – |
| Q1 FY2017CQ2 2016 | Jul 31, 2016 | $2.34M | – |
See a number that looks wrong?